TNF and inflammatory bowel disease: Although anti‐TNF‐α monoclonal antibody has become a therapeutic means to relieve IBD, ≈40% of patients have no response to anti‐TNF‐α therapy.[56] In addition, the increased risk of severe infection[57] and malignancy[58] is a cause for concern.